Skip to main content
. 2019 Feb 8;98(6):e14400. doi: 10.1097/MD.0000000000014400

Figure 4.

Figure 4

The relative benefit of statins, PCSK9 inhibitors, ezetimibe, and placebo against adverse events and neurocognitive events in patients with hypercholesterolemia. Data are presented with odds ratios and 95% confidence intervals. PCSK9 = proprotein convertase subtilisin-kexin type 9 serine protease.